We Can’t Allow a Handful of Greedy People to Play God’: Bernie Sanders Takes Aim at Big Tech Billionaires Over AI Power
Sanders is calling for tougher AI regulation, including a ban on superintelligent AI, while pushing for greater public oversight.
Stocks · News reference
Performance Comparison: Microsoft And Competitors In Software Industry
In today's rapidly changing and fiercely competitive business landscape, it is essential for investors and industry enthusiasts to thoroughly analyze companies. In this article, we will conduct a comprehensive
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
AI in Pharmaceutical Market to Hit USD 48.43 Billion by 2035, Growing at 31.76% CAGR – SNS Insider
The global AI in pharmaceutical market is projected to grow from USD 3.07 billion in 2025 to USD 48.43 billion by 2035, with a CAGR of 31.76%. The U.S. market is expected to reach USD 15.10 billion and Europe USD 12.60 billion by 2035. Growth is driven by generative AI, adaptive trials reducing patient enrollment by 40%, regulatory endorsement including FDA's qualification of AIM-NASH, and increased venture capital investment in AI-first drug discovery platforms.
The Stock Market Has Not Been This Expensive Since the Dot-com Bubble's Peak. History Says to Prepare for What Might Come Next.
The S&P 500's Shiller CAPE ratio has reached its highest level since the dot-com bubble peak, driven by unsustainable AI-related earnings gains and massive capital expenditures. While super-intelligent AI could justify current valuations, the market faces significant downside risk. Investors should maintain diversified portfolios rather than betting heavily on either scenario.